Mga Batayang Estadistika
| LEI | 549300GMXBE5NUWISF13 |
| CIK | 1609809 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Seres Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 6, 2025 |
Letter Agreement, dated July 21, 2025, by and between the Company and Marella Thorell Exhibit 10.2 July 21, 2025 Marella Thorell By email Re: Appointment as Co-CEO Dear Marella: As we have discussed, the Board wishes to offer you the position of Co-Chief Executive Officer of Seres Therapeutics, Inc. (the “Company”), effective August 1, 2025 (the “Start Date”) on the terms set forth in this letter agreement (the “Letter”). Reference is made to the Employment Agreement previously ent |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| August 6, 2025 |
Letter Agreement, dated July 21, 2025, by and between the Company and Thomas DesRosier Exhibit 10.3 July 21, 2025 Thomas J. DesRosier By email Re: Appointment as Co-CEO Dear Thomas: As we have discussed, the Board wishes to offer you the position of Co-Chief Executive Officer of Seres Therapeutics, Inc. (the “Company”), effective August 1, 2025 (the “Start Date”) on the terms set forth in this letter agreement (the “Letter”). Reference is made to the Amended and Restated Employment |
|
| August 6, 2025 |
Letter Agreement, dated July 21, 2025, by and between the Company and Eric Shaff Exhibit 10.1 July 21, 2025 Eric D. Shaff By email Re: Transition Dear Eric: You have informed Seres Therapeutics, Inc. (the “Company”) of your desire to resign your officer and employee positions with the Company. Accordingly, you and the Company agree that your employment with the Company will end on July 31, 2025 (the “Separation Date”) as set forth in this letter agreement (the “Letter”). Refer |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Ther |
|
| August 6, 2025 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematological malignancies Seres engaging with multiple parties r |
|
| August 6, 2025 |
EX-99.2 Seres Therapeutics Investor Presentation August 2025 Exhibit 99.2 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including s |
|
| July 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2025 |
Non-Employee Director Compensation Policy Exhibit 10.2 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective March 27, 2025) (the “Effective Date”) Non-employee members of the board of directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensa |
|
| May 7, 2025 |
EX-99.2 Seres Therapeutics Investor Presentation May 2025 Exhibit 99.2 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including stat |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres The |
|
| May 7, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. |
|
| May 7, 2025 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematologic |
|
| May 7, 2025 |
As filed with the Securities and Exchange Commission on May 7, 2025 As filed with the Securities and Exchange Commission on May 7, 2025 Registration No. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 22, 2025 |
EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF SERES THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Seres Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: 1. The Board of Direc |
|
| April 14, 2025 |
Seres Therapeutics, Inc. 2025 Incentive Award Plan Exhibit 10.1 SERES THERAPEUTICS, INC. 2025 INCENTIVE AWARD PLAN (AS AMENDED AND RESTATED EFFECTIVE APRIL 10, 2025) I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan ar |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| March 13, 2025 |
Seres Therapeutics, Inc. Insider Trading Compliance Policy Exhibit 19.1 Seres Therapeutics, Inc. Insider Trading Compliance Policy (As of March 29, 2023) This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by |
|
| March 13, 2025 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 le Seres Therapeutics, Inc. |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| March 13, 2025 |
Seres Therapeutics Investor Presentation March 2025 EX-99.2 Exhibit 99.2 Seres Therapeutics Investor Presentation March 2025 Seres Therapeutics Investor Presentation March 2025 Transforming patient outcomes using proprietary consortia of live biotherapeutics Strong Foundation Positive SER-155 Phase Blockbuster SER-155 Expansive Platform 1b Data in Allo-HSCT Opportunity Potential • Validated platform ® highlighted by VOWST • 77% relative risk reduct |
|
| March 13, 2025 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Seres Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) and Amended and Restated Bylaws (“Bylaws”) are summaries and are qualified in their entirety by reference to the applicable provisio |
|
| March 13, 2025 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft st |
|
| March 13, 2025 |
As filed with the Securities and Exchange Commission on March 13, 2025 As filed with the Securities and Exchange Commission on March 13, 2025 Registration No. |
|
| March 13, 2025 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 SERES THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Seres Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commiss |
|
| February 12, 2025 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 4, 2025 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
Exhibit 99.1 J.P. Morgan Conference Seres Therapeutics Investor Presentation January 16, 2025 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking sta |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2025 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to place |
|
| November 13, 2024 |
Exhibit 10.7 MUTUAL TERMINATION OF COLLABORATION AND LICENSE AGREEMENT This MUTUAL TERMINATION OF COLLABORATION AND LICENSE AGREEMENT (the “ROW License Agreement Termination Agreement”) is effective on September 30, 2024 (“ROW License Agreement Termination Effective Date”), and is made by and between Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2024 |
Exhibit 10.6 MUTUAL TERMINATION OF LICENSE AGREEMENT This MUTUAL TERMINATION OF LICENSE AGREEMENT (the “US License Agreement Termination Agreement”) is effective on September 30, 2024 (“US License Agreement Termination Effective Date”), and is made by and between Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, having an office located at 101 Cambridge Par |
|
| November 13, 2024 |
Exhibit 99.1 SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infections and systemic antibiotic exposure, as well as lower incidence of febrile neutropenia, as compared to placebo, through day 100 post allo-HSCT Financial position stren |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres |
|
| November 13, 2024 |
Seres Therapeutics Investor Presentation November 13, 2024 Exhibit 99.2 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including sta |
|
| October 11, 2024 |
Seres Therapeutics, Inc. 14,285,715 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282450 PROSPECTUS Seres Therapeutics, Inc. 14,285,715 Shares of Common Stock This prospectus relates to the resale, from time to time, of up to 14,285,715 shares of our common stock, or the shares, by the selling stockholder identified in this prospectus, or the selling stockholder. We will not receive any proceeds from the sa |
|
| October 9, 2024 |
Seres Therapeutics, Inc. 101 Cambridgepark Drive Cambridge, MA 02140 Seres Therapeutics, Inc. 101 Cambridgepark Drive Cambridge, MA 02140 October 9, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed October 1, 2024 File No. 333-282450 To whom it may concern: Pursuant to Rule 461(a) under the Securiti |
|
| October 2, 2024 |
MCRB / Seres Therapeutics, Inc. / NESTLE SA - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3) Seres Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81750R102 (CUSIP Number) Nestlé S.A. Avenue Nestlé, 55 1800 Vevey Switzerland Attention: General Counsel Corporate Facsimile: 01-41-21-924-2 |
|
| October 1, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Seres Therapeutics, Inc. |
|
| October 1, 2024 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections Cash received at completion, along wi |
|
| October 1, 2024 |
As filed with the Securities and Exchange Commission on October 1, 2024 Table of Contents As filed with the Securities and Exchange Commission on October 1, 2024 Registration No. |
|
| October 1, 2024 |
EX-10.1 Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of September 30, 2024 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (the “Investor”). RECITALS A. The Company and the |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| October 1, 2024 |
EX-10.3 Exhibit 10.3 Execution Version CROSS-LICENSE AGREEMENT This CROSS-LICENSE AGREEMENT (this “Agreement”), effective as of September 30, 2024 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”). WHEREAS, Seller and Purchaser have |
|
| October 1, 2024 |
Seres Therapeutics, Inc. Unaudited Pro Forma Combined Financial Information EX-99.2 Exhibit 99.2 Seres Therapeutics, Inc. Unaudited Pro Forma Combined Financial Information On September 30, 2024, Seres Therapeutics, Inc. (“Seres” or the “Company”) completed its previously announced sale of Seres’ VOWST microbiome therapeutic business (the “VOWST Business”) (the “Transaction”) pursuant to the Asset Purchase Agreement, dated August 5, 2024 (the “Purchase Agreement”), with S |
|
| October 1, 2024 |
EX-10.4 Exhibit 10.4 EXECUTION VERSION EMPLOYEE SUPPORT AGREEMENT This EMPLOYEE SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of September 30, 2024 (the “Effective Date”) by and between Société des Produits Nestlé S.A. (“Purchaser”) and Seres Therapeutics, Inc. (“Seller” and, together with Purchaser, the “Parties” and each, individually, a “Party”). Capitalized terms not define |
|
| October 1, 2024 |
EX-10.2 Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version TRANSITION SERVICES AGREEMENT By and Between Seres Therapeutics, Inc., and Nestlé Enterprises S.A. Dated as of September 30, 2024 |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| September 26, 2024 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS STOCKHOLDERS APPROVE SALE OF VOWST™ TO NESTLÉ HEALTH SCIENCE; SALE EXPECTED TO CLOSE ON SEPTEMBER 30 CAMBRIDGE, Mass.— September 26, 2024 — Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company’s |
|
| September 12, 2024 |
EX-99.1 Exhibit 99.1 SER-155 Phase 1b Readout September 12, 2024 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements |
|
| September 12, 2024 |
EX-99.3 Exhibit 99.3 Seres Therapeutics Investor Presentation September 12, 2024 Disclaimers Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, incl |
|
| September 12, 2024 |
EX-99.2 Exhibit 99.2 Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) SER-155 administration was associated with a significant reduction in both bacterial bloodstream infections (BSIs) and systemic antibiotic exposure, as well as lower incidence of febrile neutr |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commis |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| August 15, 2024 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 238) F-2 Consolidated Balance Sheets as of December 31, 2023 and 2022 F-4 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 F-5 Consolidated Statements of Stockholders’ (Deficit) Equity as of December 31, 2023 and 2 |
|
| August 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ D |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| August 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SCHEDULE 14A (Form Type) SERES THERAPEUTICS, INC. |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of (Commission (IRS Employer inc |
|
| August 13, 2024 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (C |
|
| August 13, 2024 |
Seres Therapeutics Investor Presentation August 13, 2024 Exhibit 99.2 Disclaimers Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including stateme |
|
| August 13, 2024 |
Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. ASSIGNMENT AND TERMINATION OF MANUFACTURING AGREEMENT This ASSIGNMENT AND TERMINATION OF MANUFACTURING AGREEMENT (the “Manufacturing Agreement Termination |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Ther |
|
| August 13, 2024 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash infusion, less approximately $20M in settlement of net obligations between the Parties, at close Transaction proceeds to fully retire debt and support advanceme |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| August 6, 2024 |
FORM OF CROSS-LICENSE AGREEMENT1 Exhibit 10.3 FORM OF CROSS-LICENSE AGREEMENT1 This Cross-License Agreement (this “Agreement”), effective as of [ ● ], 2024 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”). WHEREAS, Seller and Purchaser have entered into an Asset P |
|
| August 6, 2024 |
Exhibit 99.1 Form of Support Agreement This SUPPORT AGREEMENT (this “Agreement”) is made as of August 5, 2024, by and among Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”), and the Person set forth on Schedule A hereto (“Stockholder”). |
|
| August 6, 2024 |
Exhibit 99.2 Form of Support Agreement This SUPPORT AGREEMENT (this “Agreement”) is made as of August 5, 2024, by and among Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”), and the Person set forth on Schedule A hereto (“Stockholder”). |
|
| August 6, 2024 |
SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST™ ASSET PURCHASE AGREEMENT WITH NESTLÉ HEALTH SCIENCE Exhibit 99.1 SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST™ ASSET PURCHASE AGREEMENT WITH NESTLÉ HEALTH SCIENCE Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| August 6, 2024 |
Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT by and between SERES THERAPEUTICS, INC., as Seller, and SociÉtÉ des Produits NestlÉ S.A., as Purchaser Dated as of August 5, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND CONSTRUCTION 2 1.1 Definitions 2 1.2 Interpretation Provisions 27 1.3 Performance of Obligations by Affiliates 28 ARTICLE 2 PURCHASE AND SALE 28 2.1 Purchase and Sale |
|
| August 6, 2024 |
Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of [●], 2024 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (the “Investor”). RECITALS A. The Company and the Investor have entered into |
|
| August 6, 2024 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. FORM OF TRANSITION SERVICES AGREEMENT By and Between Seres Therapeutics, Inc., and [Société des Produits Nestlé S.A] Dated as of [ ● ], 2024 THIS TRANSITIO |
|
| August 6, 2024 |
FORM OF EMPLOYEE SUPPORT AGREEMENT Exhibit 10.4 FORM OF EMPLOYEE SUPPORT AGREEMENT This EMPLOYEE SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of [●], 2024 (the “Effective Date”) by and between Société des Produits Nestlé S.A. (“Purchaser”) and Seres Therapeutics, Inc. (“Seller” and, together with Purchaser, the “Parties” and each, individually, a “Party”). Capitalized terms not defined herein shall have the mea |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State |
|
| August 6, 2024 |
Exhibit 10.3 FORM OF CROSS-LICENSE AGREEMENT1 This Cross-License Agreement (this “Agreement”), effective as of [ ● ], 2024 (the “Effective Date”), is made by and between Seres Therapeutics, Inc., a Delaware corporation (“Seller”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”). WHEREAS, Seller and Purchaser have entered into an Asset P |
|
| August 6, 2024 |
Exhibit 2.1 EXECUTION VERSION ASSET PURCHASE AGREEMENT by and between SERES THERAPEUTICS, INC., as Seller, and SociÉtÉ des Produits NestlÉ S.A., as Purchaser Dated as of August 5, 2024 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND CONSTRUCTION 2 1.1 Definitions 2 1.2 Interpretation Provisions 27 1.3 Performance of Obligations by Affiliates 28 ARTICLE 2 PURCHASE AND SALE 28 2.1 Purchase and Sale |
|
| August 6, 2024 |
FORM OF SECURITIES PURCHASE AGREEMENT Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of [●], 2024 by and between Seres Therapeutics, Inc., a Delaware corporation (the “Company”), and Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (the “Investor”). RECITALS A. The Company and the Investor have entered into |
|
| August 6, 2024 |
SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST™ ASSET PURCHASE AGREEMENT WITH NESTLÉ HEALTH SCIENCE Exhibit 99.1 SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST™ ASSET PURCHASE AGREEMENT WITH NESTLÉ HEALTH SCIENCE Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milestone payment, and an equity investment in Seres common stock, less approximately $20M in settlement of net obligations between the Parties; anticipated deal closing in |
|
| August 6, 2024 |
Exhibit 10.4 FORM OF EMPLOYEE SUPPORT AGREEMENT This EMPLOYEE SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of [●], 2024 (the “Effective Date”) by and between Société des Produits Nestlé S.A. (“Purchaser”) and Seres Therapeutics, Inc. (“Seller” and, together with Purchaser, the “Parties” and each, individually, a “Party”). Capitalized terms not defined herein shall have the mea |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| August 6, 2024 |
Exhibit 99.2 Form of Support Agreement This SUPPORT AGREEMENT (this “Agreement”) is made as of August 5, 2024, by and among Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”), and the Person set forth on Schedule A hereto (“Stockholder”). |
|
| August 6, 2024 |
Exhibit 99.1 Form of Support Agreement This SUPPORT AGREEMENT (this “Agreement”) is made as of August 5, 2024, by and among Seres Therapeutics, Inc., a corporation organized and existing under the laws of Delaware (the “Company”), Société des Produits Nestlé S.A., a société anonyme organized under the laws of Switzerland (“Purchaser”), and the Person set forth on Schedule A hereto (“Stockholder”). |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2024 Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of (Commission (IRS Employer inco |
|
| August 6, 2024 |
Exhibit 10.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. FORM OF TRANSITION SERVICES AGREEMENT By and Between Seres Therapeutics, Inc., and [Société des Produits Nestlé S.A] Dated as of [ ● ], 2024 THIS TRANSITIO |
|
| May 8, 2024 |
Non-Employee Director Compensation Program Exhibit 10.2 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective March 19, 2024) (the “Effective Date”) Non-employee members of the board of directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensa |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres The |
|
| May 8, 2024 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Continued market adoption of VOWST® with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient starts, and net sales of $10.1 million during Q1 2024, and accelerated net sales in March and April SER-155 Phase 1b placebo-controlled Cohort 2 clinical rea |
|
| May 8, 2024 |
Advisory Agreement, dated March 15, 2024, by and between the Registrant and David Arkowitz Exhibit 10.4 SERES THERAPEUTICS, INC. ADVISORY AGREEMENT THIS ADVISORY AGREEMENT (this “Agreement”) is made and effective as of March 15, 2024 (the “Effective Date”) by and between David Arkowitz, an individual (“Advisor”), whose address is set forth on the signature page below and SERES THERAPEUTICS, Inc., a Delaware corporation (along with its affiliated companies, the “Company”) (collectively r |
|
| May 8, 2024 |
Exhibit 10.3 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between David Arkowitz (“Executive”) and Seres Therapeutics, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but not defined in this Agreement shall have the meanings set forth in the Employment Agreement |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 8, 2024 |
Employment Agreement, dated February 24, 2024, by and between the Registrant and Marella Thorell Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”), dated as of February 24, 2024, is made by and between Seres Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Marella Thorell (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS A. It is the desire of the Company |
|
| May 8, 2024 |
Form of Performance Option Agreement under the 2015 Incentive Award Plan Exhibit 10.6 Seres Therapeutics, Inc. 2015 Incentive Award Plan Stock Option Grant Notice Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2015 Incentive Award Plan (as amended from time to time, the “Plan”) of Seres Therapeutics, Inc. (the “Company”). The Company hereby grants to the participant listed below ( |
|
| May 8, 2024 |
Exhibit 10.5 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. CONFIDENTIAL September 15, 2015 SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”), effective as of September 15, 2015 (the “Effective Date”), is made a |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 8, 2024 |
Certificate of Amendment to Restated Certificate of Incorporation of Registrant, dated April 5, 2024 EX-3.1 Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF SERES THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Seres Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: 1. The Board of Direc |
|
| March 5, 2024 |
Exhibit 10.26 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. CONFIDENTIAL September 15, 2015 SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”), effective as of September 15, 2015 (the “Effective Date”), is made |
|
| March 5, 2024 |
Lease, dated September 22, 2021, by and between the Registrant and HCP/KING 101 CPD LLC Exhibit 10.6 101 CAMBRIDGEPARK DRIVE CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET Execution Date: September 22 , 2021 Tenant: Seres Therapeutics, Inc., a Delaware corporation Tenant's Mailing Address Prior to Occupancy: Seres Therapeutics, Inc. 200 Sidney Street, 4th Floor Cambridge, Massachusetts 02139 Landlord: HCP/King 101 CPD LLC, a Delaware limited liability company Building: 101 Cambridgepar |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| March 5, 2024 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through year-end 2023 Significant adoption of VOWST since launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 le Seres Therapeutics, Inc. |
|
| March 5, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. |
|
| March 5, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 SERES THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Seres Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to |
|
| March 5, 2024 |
As filed with the Securities and Exchange Commission on March 5, 2024 S-8 As filed with the Securities and Exchange Commission on March 5, 2024 Registration No. |
|
| March 5, 2024 |
Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Seres Therapeutics, Inc. (the “Company,” “we,” “us,” and “our”) and certain provisions of our Restated Certificate of Incorporation, as amended (“Certificate of Incorporation”) and Amended and Restated Bylaws (“Bylaws”) are summaries and are qualified in their entirety by reference to the applicable provisio |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commiss |
|
| February 26, 2024 |
EX-99.1 Exhibit 99.1 SERES THERAPEUTICS ANNOUNCES THE APPOINTMENT OF MARELLA THORELL AS CHIEF FINANCIAL OFFICER AND THE RETIREMENT OF DAVID ARKOWITZ February 26, 2024 CAMBRIDGE, Mass.—(BUSINESS WIRE)—February 26, 2024 — Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that Marella Thorell will join as Executive Vice President and Chief Financial O |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2024 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155 VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023 Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts SER-155 |
|
| January 9, 2024 |
EX-99.1 January 10, 2024 Seres Therapeutics Investor Presentation Exhibit 99.1 Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to the anticipated supply and degree of market acceptance of VOWST; the potential for microbiome therapeutics to protect against infection; the timing |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| January 2, 2024 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SERES THERAPEUTICS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 NOTICE OF BUSINESS TO BE BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES FOR NOMI |
|
| November 7, 2023 |
MCRB / Seres Therapeutics Inc / FEDERATED HERMES, INC. Passive Investment SC 13G/A 1 form1418.htm OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4*) SERES THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81750R102 (CUSIP Number) October 31, 2023 (Date of Event Whi |
|
| November 2, 2023 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million Rapid growth of VOWST continues with more than 1,500 patient enrollment forms received since FDA approval Announces strategic restructuring to focus resources and investment on continued VOWST growth, completion of SER-155 Phase 1b study, and supporting longer-term busine |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissio |
|
| August 11, 2023 |
Seres Therapeutics, Inc. 200 Sidney Street – 4th Floor Cambridge, MA 02139 Seres Therapeutics, Inc. 200 Sidney Street – 4th Floor Cambridge, MA 02139 August 11, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Seres Therapeutics, Inc. Registration Statement on Form S-3 Filed August 8, 2023 File No. 333-273794 To whom it may concern: Pursuant to Rule 461(a) under the Sec |
|
| August 8, 2023 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates – VOWSTTM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI (rCDI) – – VOWST early commercial uptake encouraging with strong initial demand observed |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| August 8, 2023 |
Exhibit 1.2 SERES THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT May 21, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Seres Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the te |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Ther |
|
| August 8, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Seres Therapeutics, Inc. |
|
| August 8, 2023 |
EX-4.3 Exhibit 4.3 SERES THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. E |
|
| June 28, 2023 |
EX-99.1 Exhibit 99.1 Seres Therapeutics June 2023 Corporate Overview Forward Looking Statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to the anticipated supply and degree of market acceptance of VOWST; the potential for microbiome therapeutics to protect against infe |
|
| June 28, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO RESTATED CERTIFICATE OF INCORPORATION OF SERES THERAPEUTICS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware Seres Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: 1. The Board of Directors of |
|
| June 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 10, 2023 |
MCRB / Seres Therapeutics Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3*) SERES THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81750R102 (CUSIP Number) April 30, 2023 (Date of Event Which Requires Filing of this |
|
| May 9, 2023 |
EXHIBIT 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the “Agreement”), effective as of March 13, 2023 (the “Effective Date”), is made and entered into by and between Se |
|
| May 9, 2023 |
EX-99.4 Exhibit 99.4 Seres Therapeutics Reports SER-155 Phase 1b Cohort 1 Results Showing Successful Drug Bacteria Engraftment and Substantial Reduction in Pathogen Domination in the Gastrointestinal Microbiome – Tolerability profile observed supports continued development in Cohort 2, with no treatment attributed serious adverse events – – Reduction in incidences of microbiome pathogen domination |
|
| May 9, 2023 |
EX-99.2 Seres Therapeutics Corporate Overview May 2023 Exhibit 99.2 Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to timing of VOWST product availability; the anticipated supply and degree of market acceptance of VOWST; the potential for microbiome therapeutics to protect ag |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres The |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Seres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates – VOWSTTM microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following antibacterial treatment for recurrent CDI; product availability expected in June – – New SER-155 Phase 1b Cohort 1 clinical data show favorable tolerability, succ |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 9, 2023 |
EX-99.3 SER-155 Phase 1b Cohort 1 Day 100 Data May 2023 Exhibit 99.3 SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD in Allogeneic HSCT Enrollment ongoing in SER-155 Phase 1b Cohort 2 a randomized, double-blind, placebo-controlled study Expect to release topline results in mid-2024 SER-155 is an oral, cultivated consortium, designed to reduce abundance o |
|
| April 27, 2023 |
EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT AND GUARANTY dated as of April 27, 2023 by and among SERES THERAPEUTICS, INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO as the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent U.S. $250,000,000 TABLE OF CONTENTS SECTION 1. |
|
| April 27, 2023 |
EX-4.1 Exhibit 4.1 SCHEDULE OF WARRANT HOLDERS In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the omitted executed warrants differ from the form of warrant that follows: Holder Number of Shares of Common Stock Oaktree-Forrest Multi-Strategy, LLC 3,497 INPRS Strategic Credit Holdings, LLC 3,388 Oaktree Specialty Lending Corporation |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| April 27, 2023 |
EX-99.1 Exhibit 99.1 April 27, 2023 TM VOWST FDA Approval Conference Call Forward Looking Statements Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including but not limited to the availability of VOWST product supply, the degree of market adoption and penetration, the results of payer engagement, the |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| March 7, 2023 |
EX-99.1 2 d448387dex991.htm EX-99.1 Exhibit 99.1 Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates – SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with target action date of April 26, 2023 under Prescription Drug User Fee Act (PDUFA) – – Anticipate SER-109 commercial launch soon after |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 le Seres Therapeutics, Inc. |
|
| March 7, 2023 |
Exhibit 10.28 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Amendment to LONG TERM MANUFACTURING AGREEMENT THIS AMENDMENT (the “Amendment”), to that certain Long Term Manufacturing Agreement by and between Seres Th |
|
| March 7, 2023 |
2015 Incentive Award Plan, as amended and forms of award agreements thereunder Exhibit 10.1 Seres Therapeutics, Inc. 2015 Incentive Award Plan (as amended and restated effective December 14, 2022) I. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan |
|
| March 7, 2023 |
2022 Employment Inducement Award Plan and forms of award agreements thereunder Exhibit 10.4 Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan 1. Purpose The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Section 11. 2. Eligibility Eligible |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2023 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2023 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. |
|
| March 7, 2023 |
Non-Employee Director Compensation Program Exhibit 10.5 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective February 17, 2023)(the “Effective Date”) Non-employee members of the board of directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compen |
|
| March 7, 2023 |
As filed with the Securities and Exchange Commission on March 7, 2023 S-8 As filed with the Securities and Exchange Commission on March 7, 2023 Registration No. |
|
| February 9, 2023 |
MCRB / Seres Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Seres Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 81750R102 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is file |
|
| February 1, 2023 |
MCRB / Seres Therapeutics Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ….11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2*) SERES THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81750R102 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of t |
|
| January 9, 2023 |
41st Annual J.P. Morgan Healthcare Conference January 2023 Eric Shaff, President and Chief Executive Officer Exhibit 99.1 Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to the potential approval and launch of SER-109; the anticipated indication for SER-109; the anticipated su |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 9, 2023 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported):January 4, 2023 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| December 30, 2022 |
As filed with the Securities and Exchange Commission on December 30, 2022 S-8 As filed with the Securities and Exchange Commission on December 30, 2022 Registration No. |
|
| December 30, 2022 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 2022 Employment Induceme |
|
| December 30, 2022 |
Seres Therapeutics, Inc. 2022 Employment Inducement Award Plan Exhibit 99.1 SERES THERAPEUTICS, INC. 2022 EMPLOYMENT INDUCEMENT AWARD PLAN 1. Purpose The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Section 11. 2. Eligibility Eligible |
|
| December 14, 2022 |
Exhibit 10.1 Execution version FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this ?Amendment?) is entered into as of this 9th day of December, 2022, by and between BMR-Sidney Research Campus LLC (f/k/a BMR 200-Sidney Street LLC), a Delaware limited liability company (?Landlord?), and Seres Therapeutics, Inc., a Delaware corporation (?Tenant?). RECITALS A. WHEREAS, Landlord and Tenant are |
|
| December 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 9, 2022 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation or organiz |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commissi |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres |
|
| November 2, 2022 |
Exhibit 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. CONFIDENTIAL September 15, 2015 SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (the ?Agreement?), effective as of September 15, 2015 (the ?Effective Date?), is made a |
|
| November 2, 2022 |
Exhibit 99.1 Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates ? Biologics License Application (BLA) for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection (rCDI) accepted for Priority Review by U.S. Food and Drug Administration (FDA) ? ? PDUFA target action date is April 26, 2023, with anticipated launch soon thereafter |
|
| August 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| August 3, 2022 |
Non-Employee Director Compensation Program Exhibit 10.1 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective June 22, 2022) (the “Effective Date”) Non-employee members of the board of directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensat |
|
| August 3, 2022 |
Exhibit 99.1 Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates – Expect to complete SER-109 Biologics License Application filing in the coming weeks – – Reported confirmatory SER-109 Phase 3 study results, including in individuals with a first recurrence of C. difficile infection – – Strengthened balance sheet with $100 million registered direct equity |
|
| August 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Ther |
|
| July 22, 2022 |
Share Transfer Agreement EXHIBIT 3 Share Transfer Agreement Dated as of April 29, 2022 by and between Nestl? Health Science US Holdings, Inc. |
|
| July 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Seres Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81750R102 (CUSIP Number) Nestl? S.A. Avenue Nestl?, 55 1800 Vevey Switzerland Attention: General Counsel Corporate Facsimile: 01-41-21-924-2821 with a |
|
| July 11, 2022 |
MCRB / Seres Therapeutics Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1*) SERES THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81750R102 (CUSIP Number) June 30, 2022 (Date of Event Which Requires Filing of this |
|
| July 7, 2022 |
MCRB / Seres Therapeutics Inc / Flagship VentureLabs IV, LLC - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Seres Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 81750R 10 2 (CUSIP Number) Noubar B. Afeyan, Ph.D. Flagship Pioneering 55 Cambridge Parkway, Suite 800E Cambridge, MA 02142 (617) 868-1888 (Name, Address |
|
| June 30, 2022 |
Form of Non-Affiliate Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 29, 2022, between Seres Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| June 30, 2022 |
Form of Affiliate Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of June 29, 2022, between Seres Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the terms and conditions |
|
| June 30, 2022 |
Seres Therapeutics, Inc. 200 Sidney Street—4th Floor Cambridge, MA 02139 (617) 945-9626 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-244401 PROSPECTUS SUPPLEMENT 31,746,030 Shares Common Stock We are offering 31,746,030 shares of our common stock in a registered direct offering to directly to investors, or the Investors, pursuant to this prospectus supplement and the accompanying prospectus and securities purchase agreements with certain institutional |
|
| June 30, 2022 |
Exhibit 10.3 PLACEMENT AGENCY AGREEMENT June 29, 2022 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Ladies and Gentlemen: Seres Therapeutics, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions of this Placement Agency Agreement (this ?Agreement?) and the Securities Purchase Agreement (defined below), to issue and sell to the purchas |
|
| June 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 29, 2022 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation or organizati |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 7, 2022 |
EXHIBIT 99.2 Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection ? ECOSPOR IV study shows favorable safety profile through 24-week follow-up, consistent with the safety profile observed in ECOSPOR III study ? 91.3% sustained clinical response achieved at eight weeks in overall populati |
|
| June 7, 2022 |
SER-109 ECOSPOR IV Study Results June 7, 2022 Exhibit 99.1 Some of the statements in this presentation constitute ?forward looking statements? under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and potential approval of SER-109 and its potential to be a first-in-class therapeutic; the market for SER-109; our capacity for commercial supply of SER-1 |
|
| June 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission F |
|
| May 4, 2022 |
Exhibit 99.1 Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates ? SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022 ? ? FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track |
|
| May 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres The |
|
| May 4, 2022 |
Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. March 11, 2022 NHSc Pharma Partners c/o Soci?t? des Produits Nestl? S.A. 55 Avenue Nestle 1800 Vevey, Switzerland Attn. [***] Dear [***]: Reference is made to |
|
| May 4, 2022 |
As filed with the Securities and Exchange Commission on May 4, 2022 Registration No. |
|
| April 29, 2022 |
DEF 14A 1 d244531ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Us |
|
| April 29, 2022 |
DEFA14A 1 d244531ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi |
|
| April 6, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 6, 2022 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| April 6, 2022 |
Corporate Overview April 2022 Exhibit 99.1 Some of the statements in this presentation constitute ?forward looking statements? under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its status as a first-in-class therapeutic, the timing of a BLA filing, the market for SER-109, and our capacity for commercial supply of SER-10 |
|
| March 1, 2022 |
POS AM 1 d660970dposam.htm POS AM Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. 333-244401 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO Form S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Seres Therapeutics, Inc. (Exact name of registrant as specified in its charter) |
|
| March 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Therapeutics, Inc. |
|
| March 1, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2022 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| March 1, 2022 |
Exhibit 99.1 Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates ? SER-109 Phase 3 study results in recurrent C. difficile infection published in New England Journal of Medicine ? Biologics License Application (BLA) filing for SER-109 anticipated in mid-2022 ? ? Investor webcast highlighted the broad potential of microbiome therapeutics as a |
|
| March 1, 2022 |
EX-FILING FEES 4 d683320dexfilingfees.htm EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) SERES THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table I: Newly Registered Securities Plan Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee R |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on March 1, 2022 As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Post-Effective Amendment No. 1 Table of Contents As filed with the Securities and Exchange Commission on March 1, 2022 Registration No. |
|
| March 1, 2022 |
Employment Agreement, dated January 5, 2022, by and between the Registrant and Paula Cloghessy Exhibit 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of January 5, 2022, is made by and between Seres Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Paula Cloghessy (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS A. It is the desire of the Company |
|
| March 1, 2022 |
Exhibit 10.19 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?), dated as of February 24, 2022 (the ?Second Amendment Effective Date?), is made by and among Seres Therapeutics, Inc., a Delaware corporation, and each of its Subsidiaries from time to time party to the Loan Agreement (individually or collectively, as the context ma |
|
| March 1, 2022 |
EX-FILING FEES 4 d657964dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Seres Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(3) Proposed Maximum Offering Price Per Unit Maximum |
|
| March 1, 2022 |
Exhibit 10.25 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item (601)(b)(10). Such excluded information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. EXECUTION VERSION LONG TERM MANUFACTURING AGREEMENT THIS LONG TERM MANUFACTURING AGREEMENT (the ?Agreement?), effective as of November 8, 2021 (the ?Effec |
|
| February 14, 2022 |
MCRB / Seres Therapeutics Inc / Nikko Asset Management Americas, Inc. - SC13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Seres Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81750R102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* SERES THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 81750R102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
MCRB / Seres Therapeutics Inc / FEDERATED HERMES, INC. Passive Investment OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ?.11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) SERES THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 81750R102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of th |
|
| February 10, 2022 |
MCRB / Seres Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Seres Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 81750R102 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule 13d-1(b) ? |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Seres Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 81750R102 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 10, 2021 |
Exhibit 99.1 Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates ? Enrollment completed in SER-109 recurrent C. difficile infection open-label study? ? Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Biologics License Application (BLA) filing in mid-2022 ? ? Collaboration with Bacthera A.G |
|
| November 10, 2021 |
License Agreement, dated July 1, 2021, by and between the Registrant and NHSc Pharma Partners EXHIBIT 10.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. Execution Version LICENSE AGREEMENT THIS LICENSE AGREEMENT (?Agreement?), dated as of July 1, 2021 (the ?Effective Date?) is entered into between Seres Therap |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commiss |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres |
|
| November 10, 2021 |
Letter Agreement, dated November 4, 2021, by and between the Registrant and David S. Ege, Ph.D. EXHIBIT 10.2 Seres Therapeutics, Inc. 200 Sidney Street Cambridge, MA 02139 November 4, 2021 Dear Dr. Ege, Seres Therapeutics, Inc. (the ?Company?) has agreed to pay you a one-time special cash bonus in the lump sum amount of $131,000 (the ?Special Bonus?), less tax withholdings required by law, subject to the terms hereof. The Special Bonus will be paid to you within thirty (30) days following th |
|
| November 10, 2021 |
Non-Employee Director Compensation Program EXHIBIT 10.3 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective June 16, 2021) Non-employee members of the board of directors (the ?Board?) of Seres Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this P |
|
| August 3, 2021 |
Non-Employee Director Compensation Program Exhibit 10.3 Seres Therapeutics, Inc. Non-Employee Director Compensation Program (as amended effective June 2, 2021) Non-employee members of the board of directors (the ?Board?) of Seres Therapeutics, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Pr |
|
| August 3, 2021 |
Exhibit 99.1 Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates ? SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 ? ? SER-109 co-commercialization agreement with Nestl? Health Science provides $310 million in upfront and contingent approval milestones, additional $225 millio |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37465 Seres Ther |
|
| August 3, 2021 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ?Agreement?), dated as of January 29, 2021 (the ?Effective Date?), is made by and between Seres Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and David Ege, Ph.D (?Executive?) (collectively referred to as the ?Parties? or individually referr |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2021 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| July 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2021 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission |
|
| July 22, 2021 |
Exhibit 99.1 Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis ?Primary endpoint of clinical remission compared to placebo was not achieved? ?Both dosing regimens of SER-287 were generally well tolerated? ?Open label and maintenance portions of the SER-287 study will be closed? ? Microbiome endpoints and analyses expected in the second h |
|
| July 1, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2021 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation or organizatio |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2021 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 21, 2021 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-244401 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.001 par value $150,000,000 $16,365 (1) The registration fee has been calculated pursuant to Rule 457(o) based on the Maximum Aggregate Offering Price and Rule |
|
| May 21, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 21, 2021 SERES THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation or organizatio |
|
| May 21, 2021 |
Exhibit 1.1 SERES THERAPEUTICS, INC. $150,000,000 COMMON STOCK SALES AGREEMENT May 21, 2021 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Seres Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the te |
|
| May 20, 2021 |
Employment Agreement, dated May 10, 2021 by and between the Registrant and David Arkowitz Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?), dated as of May 10, 2021, is made by and between Seres Therapeutics, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and David Arkowitz (?Executive?) (collectively referred to as the ?Parties? or individually referred to as a ?Party?). RECITALS A. It is the desire of the Company to as |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 SERES THERAPEUTICS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-37465 27-4326290 (State or other jurisdiction of incorporation) (Commission F |
|
| May 20, 2021 |
Exhibit 99.1 Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development May 20, 2021 8:00 AM Eastern Standard Time CAMBRIDGE, Mass.? Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective |
